ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
7 |
31/03/24 |
31/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
8 |
31/03/24 |
31/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Wilba32
|
273 |
124K |
3 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
273
|
124K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Wilba32
|
273 |
124K |
3 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
273
|
124K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Wilba32
|
273 |
124K |
1 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
273
|
124K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
Wilba32
|
1.4K |
365K |
22 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
1.4K
|
365K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
4 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
4 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
Wilba32
|
623 |
272K |
8 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
623
|
272K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Wilba32
|
5.4K |
2.7M |
29 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
5.4K
|
2.7M
|
29
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Wilba32
|
9.9K |
2.9M |
2 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
9.9K
|
2.9M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
Wilba32
|
623 |
272K |
7 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
623
|
272K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
664 |
271K |
5 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
664
|
271K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
664 |
271K |
3 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
664
|
271K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
Wilba32
|
623 |
272K |
7 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
623
|
272K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
664 |
271K |
4 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
664
|
271K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
5 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
5 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
18 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
16 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
14 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
12 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Wilba32
|
1.0K |
418K |
11 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
418K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
3 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
3 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
2 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
4 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
2 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
4 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
3 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
6 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
6 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
12 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Wilba32
|
226 |
82K |
17 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
82K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
664 |
271K |
8 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
664
|
271K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
664 |
271K |
14 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
664
|
271K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Wilba32
|
664 |
271K |
20 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
664
|
271K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Partnership deals......
|
|
Wilba32
|
102 |
21K |
7 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
102
|
21K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Partnership deals......
|
|
Wilba32
|
102 |
21K |
3 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
102
|
21K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Wilba32
|
549 |
179K |
7 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
549
|
179K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Wilba32
|
85 |
23K |
2 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
85
|
23K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Wilba32
|
85 |
23K |
4 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
85
|
23K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Wilba32
|
17K |
6.7M |
4 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
17K
|
6.7M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Wilba32
|
17K |
6.7M |
35 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
17K
|
6.7M
|
35
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
Wilba32
|
222 |
49K |
2 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
222
|
49K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Wilba32
|
549 |
179K |
6 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
549
|
179K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Wilba32
|
549 |
179K |
11 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
549
|
179K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
Wilba32
|
168 |
101K |
7 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
168
|
101K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Shareholder Class Action (VID268/2022) – Notice to Group Members
|
|
Wilba32
|
168 |
101K |
9 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
168
|
101K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Wilba32
|
17K |
6.7M |
14 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
17K
|
6.7M
|
14
|
|